STAT3 and cancer: A number of small-molecule inhibitors of STAT3 (KI16; BP-5–087; WP1066) are currently in development and combination therapies, with BCR-ABL1 or BRAF inhibitors, have shown positive results in the treatment of several cancer types[223–225].